Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
2019 novel coronavirus disease
COVID-19
Japan
SARS-CoV-2
antibodies
antibody responses
coronavirus
coronavirus disease
diagnostics
immunology
respiratory infections
serology
seroprevalence
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
entrez:
26
1
2021
pubmed:
27
1
2021
medline:
3
2
2021
Statut:
ppublish
Résumé
We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. Of 7,950 samples, 8 were positive by both assays. Using 2 reliable antibody tests in conjunction is an effective method for estimating seroprevalence in low prevalence settings.
Identifiants
pubmed: 33496235
doi: 10.3201/eid2702.204088
pmc: PMC7853542
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
628-631Références
J Clin Med. 2020 Oct 01;9(10):
pubmed: 33019628
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Clin Microbiol Infect. 2020 Dec;26(12):1703-1705
pubmed: 32653658
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Lancet Microbe. 2020 Jul;1(3):e111-e118
pubmed: 33230504